Amarin reported $3K in Interest Expense on Debt for its fiscal quarter ending in December of 2024.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amarin USD 3K 5K Dec/2024
AstraZeneca USD 484M 181M Dec/2025
BioCryst Pharmaceuticals USD 24.45M 381K Dec/2024
DBV Technologies USD 461K 323.71K Mar/2025
Esperion Therapeutics USD 15.08M 1.36M Sep/2024
GlaxoSmithKline GBP 188M 21M Dec/2025
Halozyme Therapeutics USD 4.91M 615K Dec/2025
Heron Therapeutics USD 500K 900K Sep/2024
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
Nektar Therapeutics USD 6.02M 420K Sep/2024
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 281M 8M Sep/2025